• Explore /
  • Poster
  • / Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial.

Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial.

Abstract Video & Slides Poster

Authors

null

Patricia Pautier

Institut Gustave Roussy, and GINECO, Villejuif, France

Patricia Pautier , Philipp Harter , Carmela Pisano , Claire Cropet , Susana Hernando Polo , Regina Berger , Takashi Matsumoto , Ignace Vergote , Nicoletta Colombo , Trine Jakobi Noettrup , Georges Garnier , Peter Hillemanns , Claudio Zamagni , Antonio Gonzalez Martin , Claudia Lefeuvre-Plesse , Dominik Denschlag , Alain Lortholary , Jalid Sehouli , Frederic Selle , Isabelle Laure Ray-Coquard

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02477644

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 5514)

DOI

10.1200/JCO.2021.39.15_suppl.5514

Abstract #

5514

Abstract Disclosures

Similar Posters

First Author: Philipp Harter

First Author: Helene Blons

First Author: Jean Emmanuel Kurtz

First Author: Domenica Lorusso